Related Experiment Video
Updated: Jun 13, 2026

A Familiarization Protocol Facilitates the Participation of Children with ASD in Electrophysiological Research
Published on: July 31, 2017
Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder
Shu-Chi Huang1, Shih-Jen Tsai, Hao-Jan Yang
1Department of Psychiatry, Chung-Shan Medical University Hospital, Taichung, Taiwan.
Insights
Aripiprazole, an atypical antipsychotic, shows promise for treating behavioral issues in children with pervasive developmental disorders. This medication improved social interaction and reduced anxiety in a small case study.
Area of Science:
- Child and Adolescent Psychiatry
- Neurodevelopmental Disorders
- Pharmacology
Background:
- Aripiprazole is an atypical antipsychotic effective for childhood psychosis.
- Limited data exists on aripiprazole's efficacy and safety in pervasive developmental disorders (PDDs).
- Behavioral syndromes frequently co-occur with PDDs in children.
Observation:
- Three children diagnosed with PDDs were treated with aripiprazole.
- The treatment targeted associated behavioral syndromes.
- Case reports detail the observed effects of aripiprazole.
Findings:
- Aripiprazole significantly enhanced social interaction in all three pediatric patients.
- Two of the three children experienced notable improvements in depression and anxiety symptoms.
- The study observed positive outcomes in managing behavioral comorbidities in PDDs.
Implications:
- Aripiprazole may be a viable therapeutic option for children with PDDs.
- Further research is warranted to confirm these preliminary findings.
- This suggests a potential role for atypical antipsychotics in managing complex behavioral presentations in PDDs.
Abstract:
Aripiprazole, an atypical antipsychotic, is effective in children with psychosis and few adverse effects have been reported. However, little is known about the efficacy and safety of aripiprazole in the treatment of autistic or other pervasive developmental disorders. We report three children with pervasive developmental disorders who were treated with aripiprazole for associated behavioral syndromes. Aripiprazole significantly improved the social interaction of all three children. Furthermore, two patients also showed significant improvement in depression/anxiety syndromes. The outcomes achieved with aripiprazole in these cases suggest that it is a potential therapeutic agent for children with pervasive developmental disorders.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Antisocial Personality Disorder
Behavioral Characteristics and...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Antipsychotic Drugs: Typical and Atypical Agents
